Risk of lympho-haematological malignancies in patients with chronic plaque psoriasis: a systematic review with meta-analysis.

[1]  D. Gladman,et al.  Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. , 2020, Seminars in arthritis and rheumatism.

[2]  P. Gisondi,et al.  Topographic Differential Diagnosis of Chronic Plaque Psoriasis: Challenges and Tricks , 2020, Journal of clinical medicine.

[3]  F. Carbonnel,et al.  Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.

[4]  J. Askling,et al.  Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype. , 2020, Rheumatology.

[5]  J. Thyssen,et al.  Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease - A systematic review and meta-analysis. , 2020, Journal of Crohn's & colitis.

[6]  L. Skov,et al.  Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. , 2020, JAMA dermatology.

[7]  C. Massone,et al.  Risk of mycosis fungoides in psoriatic patients: a critical review , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  Kyungdo Han,et al.  Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population‐based cohort study , 2018, The Journal of dermatology.

[9]  H. Prince,et al.  Psoriasis and cancer. An Australian/New Zealand narrative , 2018, The Australasian journal of dermatology.

[10]  L. Skov,et al.  Psoriasis and risk of malignant lymphoma: a population‐based cohort study , 2018, The British journal of dermatology.

[11]  M. Lebwohl,et al.  Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry , 2017, Journal of the American Academy of Dermatology.

[12]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[13]  B. Nordstrom,et al.  The risk of malignancy among biologic‐naïve pediatric psoriasis patients: A retrospective cohort study in a US claims database , 2017, Journal of the American Academy of Dermatology.

[14]  X. Mariette,et al.  Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. , 2017, Journal of autoimmunity.

[15]  J. Askling,et al.  Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? , 2017, Arthritis & rheumatology.

[16]  Thomas G. Ray,et al.  Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population , 2017, Journal of the American Academy of Dermatology.

[17]  M. Weinstock,et al.  Personal history of psoriasis and risk of incident cancer among women: a population‐based cohort study , 2016, The British journal of dermatology.

[18]  Daniel B. Shin,et al.  The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network. , 2016, JAMA dermatology.

[19]  R. Dummer,et al.  European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. , 2015, Journal of Crohn's & colitis.

[20]  Ellen J. Kim,et al.  The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. , 2015, Dermatologic clinics.

[21]  K. Hemminki,et al.  Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  K. Hemminki,et al.  Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype. , 2014 .

[23]  R. Rosenquist,et al.  Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces? , 2014, Seminars in cancer biology.

[24]  M. Maître,et al.  Risk of cancer in psoriasis: a systematic review and meta‐analysis of epidemiological studies , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  K. Reich,et al.  Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate‐to‐severe plaque psoriasis: results of a randomized, long‐term extension trial (RESTORE2) , 2013, The British journal of dermatology.

[26]  E. Petridou,et al.  Cigarette smoking and risk of lymphoma in adults: a comprehensive meta-analysis on Hodgkin and non-Hodgkin disease , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[27]  M. Lai,et al.  The risk of developing non‐melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10‐year, population‐based cohort study , 2012, International journal of dermatology.

[28]  M. Suarez‐Almazor,et al.  Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.

[29]  K. Papp,et al.  Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. , 2012, Journal of the American Academy of Dermatology.

[30]  E. Sasso,et al.  Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. , 2012, Journal of the American Academy of Dermatology.

[31]  Tzeng-Ji Chen,et al.  The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. , 2011, Journal of the American Academy of Dermatology.

[32]  M. Lichtman.  Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma , 2010, The oncologist.

[33]  P. Allavena,et al.  Molecular pathways and targets in cancer-related inflammation , 2010, Annals of medicine.

[34]  S. Piana,et al.  Folliculotropic mycosis fungoides in a psoriatic patient under methotrexate treatment , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[35]  S. Jick,et al.  Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. , 2009, The Journal of investigative dermatology.

[36]  P. Fadda,et al.  Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. , 2009, Cancer research.

[37]  D. Moher,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.

[38]  K. Hemminki,et al.  Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden , 2009, British Journal of Cancer.

[39]  J. Mitri,et al.  Diabetes and Risk of Non-Hodgkin's Lymphoma , 2008, Diabetes Care.

[40]  David Altshuler,et al.  Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus , 2008, Nature Genetics.

[41]  F. Frasca,et al.  The role of insulin receptors and IGF-I receptors in cancer and other diseases , 2008, Archives of physiology and biochemistry.

[42]  Daniel B. Shin,et al.  The risk of lymphoma in patients with psoriasis. , 2006, The Journal of investigative dermatology.

[43]  R. Stern.  Lymphoma risk in psoriasis: results of the PUVA follow-up study. , 2006, Archives of dermatology.

[44]  M. Kashani-Sabet,et al.  Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. , 2003, Journal of the American Academy of Dermatology.

[45]  D. Margolis,et al.  Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. , 2003, Archives of dermatology.

[46]  K. Gatter,et al.  Lymphoproliferative disorders in Oxford renal transplant recipients , 2003, Journal of clinical pathology.

[47]  L. Dubertret,et al.  Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. , 2003, The Journal of investigative dermatology.

[48]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[49]  P. Boffetta,et al.  Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. , 2001, The Journal of investigative dermatology.

[50]  D. Margolis,et al.  The risk of malignancy associated with psoriasis. , 2001, Archives of dermatology.

[51]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[52]  A. Hannuksela-Svahn,et al.  Psoriasis, its treatment, and cancer in a cohort of Finnish patients. , 2000, The Journal of investigative dermatology.

[53]  A. Hannuksela-Svahn,et al.  Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. , 1999, Journal of the American Academy of Dermatology.

[54]  G. Frentz,et al.  Malignant tumours and psoriasis: a follow‐up study , 1999, The British journal of dermatology.

[55]  J. Karvonen,et al.  Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. , 1996, Journal of the American Academy of Dermatology.

[56]  D. Federman,et al.  The epidemiology of non-Hodgkin's lymphoma. , 1996, Connecticut medicine.

[57]  J. Olsen,et al.  Malignant tumors in patients with psoriasis. , 1992, Journal of the American Academy of Dermatology.

[58]  A. Kimball,et al.  OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. , 2015, Journal of the American Academy of Dermatology.

[59]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[60]  Miguel A Hernán,et al.  The hazards of hazard ratios. , 2010, Epidemiology.

[61]  Philippe Lafaille,et al.  Exacerbation of undiagnosed mycosis fungoides during treatment with etanercept. , 2009, Archives of dermatology.